Genen­tech touts pos­i­tive Phase III da­ta for Tecen­triq/Avastin com­bo in liv­er can­cer

The Tecen­triq and Avastin com­bi­na­tion met its pri­ma­ry end­point — re­cur­rence-free sur­vival — for peo­ple with liv­er can­cer, specif­i­cal­ly ear­ly-stage he­pa­to­cel­lu­lar car­ci­no­ma, in a Phase III study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER